Subtopic Deep Dive
PARP Inhibitors in BRCA-Mutant Cancers
Research Guide
What is PARP Inhibitors in BRCA-Mutant Cancers?
PARP inhibitors exploit synthetic lethality in BRCA1/2-mutant cancers by trapping PARP on DNA and preventing repair of double-strand breaks.
Olaparib and niraparib show high efficacy in BRCA-mutant ovarian, breast, prostate, and pancreatic cancers through clinical trials demonstrating progression-free survival benefits (Fong et al., 2009; Moore et al., 2018; Mirza et al., 2016). Over 35,000 citations across 10 key papers validate biomarker-driven responses. Resistance mechanisms and combination therapies remain active research areas.
Why It Matters
PARP inhibitors like olaparib extend progression-free survival by 70% in BRCA-mutant ovarian cancer maintenance therapy, enabling precision medicine in 15-20% of high-grade serous ovarian cases (Moore et al., 2018). In prostate cancer, olaparib achieves 33% response rates in DNA-repair deficient tumors, shifting treatment from chemotherapy to targeted therapy (Mateo et al., 2015; de Bono et al., 2020). Germline BRCA testing now guides adjuvant olaparib in breast cancer, reducing recurrence risk by 43% (Tutt et al., 2021). These advances improve survival in genetically defined subsets across multiple cancers.
Key Research Challenges
PARP Inhibitor Resistance
BRCA-mutant tumors develop resistance via BRCA reversion mutations or loss of 53BP1, restoring homologous recombination (Bouwman et al., 2010). Clinical trials show initial responses followed by progression in 50-70% of patients (Fong et al., 2009). Combination strategies with angiogenesis inhibitors partially overcome this (Ray-Coquard et al., 2019).
Biomarker Selection Accuracy
Germline BRCA testing identifies responders, but somatic mutations and HRD scores predict broader efficacy, complicating patient stratification (Pritchard et al., 2016). Ovarian cancer studies report 11.8% germline mutation rate in metastatic prostate cancer versus localized disease (Alsop et al., 2012). Functional assays are needed beyond sequencing.
Optimal Combination Therapies
Olaparib plus bevacizumab extends PFS in HRD-positive ovarian cancer, but toxicity limits use (Ray-Coquard et al., 2019). Trials in pancreatic cancer show modest benefits in germline BRCA carriers (Golan et al., 2019). Identifying synergistic partners remains unresolved.
Essential Papers
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · 2009 · New England Journal of Medicine · 3.6K citations
Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCA2 mutation. (ClinicalTrials.gov number, NC...
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia et al. · 2018 · New England Journal of Medicine · 2.7K citations
The use of maintenance therapy with olaparib provided a substantial benefit with regard to progression-free survival among women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation,...
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt et al. · 2016 · New England Journal of Medicine · 2.4K citations
Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receivin...
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Joaquı́n Mateo, Suzanne Carreira, Shahneen Sandhu et al. · 2015 · New England Journal of Medicine · 2.1K citations
Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate. (...
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi et al. · 2020 · New England Journal of Medicine · 2.1K citations
In men with metastatic castration-resistant prostate cancer who had disease progression while receiving enzalutamide or abiraterone and who had alterations in genes with a role in homologous recomb...
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
Talia Golan, Pascal Hammel, Michele Reni et al. · 2019 · New England Journal of Medicine · 2.1K citations
Among patients with a germline <i>BRCA</i> mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo. (Funded by AstraZeneca and ot...
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata et al. · 2019 · New England Journal of Medicine · 1.9K citations
In patients with advanced ovarian cancer receiving first-line standard therapy including bevacizumab, the addition of maintenance olaparib provided a significant progression-free survival benefit, ...
Reading Guide
Foundational Papers
Start with Fong et al. (2009, 3582 citations) for initial olaparib proof-of-concept in BRCA carriers, then Kaufman et al. (2014, 1651 citations) for multi-cancer expansion, establishing synthetic lethality clinical validation.
Recent Advances
Study Moore et al. (2018) for ovarian maintenance PFS data, de Bono et al. (2020) for prostate approvals, and Tutt et al. (2021) for breast adjuvant benefits.
Core Methods
Clinical trial designs use PFS endpoints with BRCA/HRD stratification; Kaplan-Meier survival analysis; next-generation sequencing for mutations (Mateo et al., 2015).
How PapersFlow Helps You Research PARP Inhibitors in BRCA-Mutant Cancers
Discover & Search
Research Agent uses searchPapers('PARP inhibitors BRCA ovarian cancer') to retrieve Fong et al. (2009, 3582 citations), then citationGraph reveals forward citations like Moore et al. (2018), and findSimilarPapers expands to niraparib trials (Mirza et al., 2016). exaSearch uncovers resistance mechanisms linking to Bouwman et al. (2010).
Analyze & Verify
Analysis Agent applies readPaperContent on Moore et al. (2018) to extract 70% PFS hazard ratio, verifies claims with CoVe against raw trial data, and runPythonAnalysis computes survival curves from Kaplan-Meier estimates using pandas. GRADE grading scores olaparib evidence as high-quality level 1b from RCTs.
Synthesize & Write
Synthesis Agent detects gaps in resistance mechanisms post-Fong et al. (2009), flags contradictions between germline vs. somatic response rates, and uses exportMermaid for synthetic lethality pathway diagrams. Writing Agent employs latexEditText for trial comparison tables, latexSyncCitations for 10-paper bibliographies, and latexCompile for publication-ready reviews.
Use Cases
"Extract and plot PFS hazard ratios from olaparib BRCA ovarian trials"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Moore 2018, Mirza 2016) → runPythonAnalysis (pandas forest plot of HR 0.30, 0.45) → matplotlib survival curves output.
"Compile LaTeX review of PARP inhibitors in prostate cancer with citations"
Research Agent → citationGraph (Mateo 2015 → de Bono 2020) → Synthesis Agent → gap detection → Writing Agent → latexEditText (add PROfound trial section) → latexSyncCitations → latexCompile → PDF review.
"Find analysis code for BRCA mutation frequency in cancer cohorts"
Research Agent → paperExtractUrls (Pritchard 2016) → paperFindGithubRepo → githubRepoInspect (mutation caller scripts) → runPythonAnalysis (re-run on TCGA data) → prevalence 11.8% verified.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ BRCA-PARP papers: searchPapers → citationGraph → GRADE all RCTs → structured report with PFS meta-analysis. DeepScan applies 7-step verification to Fong et al. (2009) claims, using CoVe checkpoints and runPythonAnalysis for toxicity stats. Theorizer generates hypotheses on 53BP1 loss resistance from Bouwman et al. (2010) linked to clinical failures.
Frequently Asked Questions
What defines PARP inhibitor efficacy in BRCA-mutant cancers?
Synthetic lethality from PARP trapping in HR-deficient BRCA1/2-mutant cells, shown by 50% response rates in olaparib trials (Fong et al., 2009; Kaufman et al., 2014).
What are key methods in PARP inhibitor trials?
Phase II/III RCTs measure PFS as primary endpoint with BRCA germline testing for stratification; olaparib 400mg BID vs. placebo in maintenance settings (Moore et al., 2018; Mirza et al., 2016).
What are the most cited papers?
Fong et al. (2009, 3582 citations) first demonstrated olaparib activity; Moore et al. (2018, 2683 citations) showed 70% PFS benefit in ovarian cancer (NEJM).
What open problems exist?
Overcoming resistance via reversion mutations; expanding beyond germline BRCA to HRD biomarkers; optimizing combinations without added toxicity (Ray-Coquard et al., 2019).
Research PARP inhibition in cancer therapy with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching PARP Inhibitors in BRCA-Mutant Cancers with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the PARP inhibition in cancer therapy Research Guide